• 1
    Cockroft JR, Pedersen ME. Beta-blockade: benefits beyond blood pressure reduction? J Clin Hypertens (Greenwich). DOI: 10.1111/j.1751-7176.2011.00552.x.
  • 2
    Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566.
  • 3
    Brixius K, Bundkirchen A, Bölck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in the human myocardium. Br J Pharmacol. 2001;133:13301338.
  • 4
    Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009;3:329334.
  • 5
    Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens. 2006;24:581589.